CORESTEMCHEMON Inc. Logo

CORESTEMCHEMON Inc.

Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.

166480 | KO

Overview

Corporate Details

ISIN(s):
KR7166480004
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로255번길 24 (삼평동), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CORESTEMCHEMON Inc. is a biotechnology corporation operating through two primary divisions: Bio-pharmaceuticals and a Nonclinical Contract Research Organization (CRO). The Bio-pharmaceutical division focuses on developing novel stem cell therapies for intractable conditions, with clinical trials targeting neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), multiple sclerosis, and cerebellar ataxia, as well as autoimmune disorders such as systemic lupus erythematosus (SLE). The Nonclinical CRO division provides essential preclinical services, conducting toxicity and efficacy evaluations for a wide range of clients in the pharmaceutical, biopharmaceutical, medical device, and cosmetic industries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 8.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 38.9 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 291.4 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 44.4 KB
2025-09-08 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.5 MB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.8 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.4 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.0 MB
2025-08-08 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.4 MB
2025-07-28 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 21.4 KB
2025-07-21 00:00
Capital/Financing Update
교환사채(해외교환사채포함)발행후만기전사채취득 (제2회차)
Korean 9.9 KB
2025-07-21 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.8 KB

Automate Your Workflow. Get a real-time feed of all CORESTEMCHEMON Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORESTEMCHEMON Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORESTEMCHEMON Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.